Elite Journal of Immunology. Volume 2 Issue 6(2024), Pp. 53-62
https://epjournals.com/journals/EJI

HIV and T-Cell Exhaustion in Pediatric Populations

*Emmanuel Ifeanyi Obeagu

Department of Medical Laboratory Science, Kampala International University, Uganda.

*Corresponding authour: Emmanuel Ifeanyi Obeagu, Department of Medical Laboratory Science, Kampala International University, Uganda, emmanuelobeagu@yahoo.com, ORCID: 0000-0002-4538-0161

Abstract

HIV infection in pediatric populations presents unique immunological challenges, particularly regarding T-cell exhaustion, a state of diminished T-cell functionality arising from chronic antigen exposure. This review explores the mechanisms and implications of T-cell exhaustion in children living with HIV, highlighting the effects of persistent viral replication on immune responses. The characteristics of T-cell exhaustion in HIV-infected pediatric patients are discussed, including the upregulation of inhibitory receptors, transcriptional changes, and the impact of chronic immune activation on overall health outcomes. T-cell exhaustion has profound clinical implications for pediatric HIV patients, including impaired viral control, reduced vaccine efficacy, increased susceptibility to co-infections, and long-term immune dysfunction. These challenges underscore the urgent need for effective therapeutic strategies aimed at restoring T-cell function. Current interventions, such as antiretroviral therapy (ART), immune checkpoint inhibitors, therapeutic vaccines, cytokine therapy, and adoptive T-cell therapy, are examined for their potential to overcome T-cell exhaustion and improve immune responses in children living with HIV.

Keywords*: HIV, T-cell exhaustion, pediatric populations, immune dysfunction, antiretroviral therapy*

Introduction

HIV infection continues to pose a significant public health challenge worldwide, particularly among pediatric populations. While considerable advances have been made in the prevention and treatment of HIV, children remain disproportionately affected by the virus, especially in regions with limited access to healthcare. According to the World Health Organization (WHO), approximately 1.7 million children under the age of 15 are living with HIV, with a substantial number acquiring the virus through vertical transmission during childbirth or breastfeeding. The unique immunological characteristics of infants and young children complicate the management of HIV, often leading to a more rapid progression of disease compared to adults.[1-4] One of the most critical issues faced by HIV-infected children is T-cell exhaustion, a phenomenon characterized by the progressive loss of T-cell effector function due to chronic antigen stimulation. T-cell exhaustion arises when T-cells are persistently exposed to high levels of antigens, as seen in chronic infections like HIV. Exhausted T-cells exhibit a distinct phenotype, marked by the upregulation of inhibitory receptors such as programmed cell death protein 1 (PD-1), cytotoxic T-lymphocyte-associated protein 4 (CTLA-4), and T-cell immunoglobulin and mucin domain-containing protein 3 (TIM-3). These inhibitory receptors dampen T-cell receptor (TCR) signaling and reduce the overall functionality of T-cells, impairing the immune response against HIV and

Citation: Obeagu EI. HIV and T-Cell Exhaustion in Pediatric Populations. Elite Journal of Immunology, 2024; 2(6): 53-62

other pathogens.[5-8] In pediatric populations, T-cell exhaustion is particularly concerning due to the immature immune system of young children. The developmental stage of the immune system in infants and toddlers results in distinct patterns of immune responses compared to adults. In HIV-infected children, T-cell exhaustion can hinder the ability to control viral replication effectively, leading to increased viral loads and greater susceptibility to opportunistic infections. Furthermore, the chronic immune activation associated with HIV can have long-term effects on immune system development, potentially resulting in lifelong immune dysfunction.[9-10]

Several factors contribute to the development of T-cell exhaustion in HIV-infected children, including persistent viral replication, the influence of co-infections, and the impact of antiretroviral therapy (ART). While ART has been instrumental in reducing viral loads and preventing disease progression, its effects on reversing T-cell exhaustion remain limited. Consequently, additional therapeutic interventions are needed to restore T-cell function and improve immune responses in these young patients.[11-12] Recent research has focused on exploring innovative approaches to overcome T-cell exhaustion in HIV-infected individuals. Immune checkpoint inhibitors, which target inhibitory receptors such as PD-1 and CTLA-4, have shown promise in reactivating exhausted T-cells and enhancing their antiviral activity. Additionally, therapeutic vaccines designed to boost T-cell responses against HIV antigens may provide a complementary strategy to restore immune function. Cytokine therapies and adoptive T-cell transfer are also being investigated as potential interventions to enhance T-cell proliferation and restore effector functions.[13-16]

In addition to treatment strategies, understanding the clinical implications of T-cell exhaustion in pediatric HIV patients is essential for guiding management decisions. The consequences of T-cell exhaustion extend beyond impaired viral control; they also include reduced vaccine efficacy and increased susceptibility to co-infections. These factors contribute to the overall morbidity and mortality associated with pediatric HIV infection, underscoring the need for comprehensive strategies that address both viral suppression and immune restoration.[17-19] Despite the growing body of research on T-cell exhaustion in HIV, there remains a critical need for further investigation into its specific characteristics and mechanisms in pediatric populations. Studies aimed at elucidating the long-term effects of T-cell exhaustion on immune development and function in HIV-infected children are essential for informing treatment approaches. Additionally, exploring the interactions between T-cell exhaustion, co-infections, and immune responses to vaccinations will provide valuable insights into the complexities of managing HIV in young patients.[20-22]

T-Cell Exhaustion in HIV

T-cell exhaustion is a critical aspect of the immune response to chronic infections, particularly in the context of HIV. It refers to a state of T-cell dysfunction characterized by a progressive loss of effector functions, including reduced cytokine production, impaired proliferation, and decreased cytotoxic activity. This phenomenon is primarily driven by the persistent exposure to viral antigens, which leads to chronic stimulation of the immune system. In HIV-infected individuals, T-cell exhaustion poses significant challenges for viral control and overall immune health.[23-24]

Continuous exposure to HIV antigens leads to the persistent activation of T-cells. While initial activation is necessary for an effective immune response, prolonged antigen stimulation results in a state of dysfunction. The constant presence of viral particles and infected cells forces T-cells to continuously engage, leading to their eventual exhaustion.[25-26] One of the hallmarks of exhausted

T-cells is the upregulation of inhibitory receptors such as PD-1, CTLA-4, and TIM-3. These receptors serve as negative regulators of T-cell activation and function. The binding of ligands to these receptors inhibits T-cell receptor (TCR) signaling, reducing T-cell proliferation and cytokine production. High levels of PD-1 expression, for example, are associated with reduced effector function and increased susceptibility to apoptosis.[27-28] Exhausted T-cells undergo significant transcriptional reprogramming and epigenetic modifications that reinforce their dysfunctional state. Key transcription factors, such as T-bet, Eomes, and Blimp-1, play crucial roles in determining T-cell fate. In exhausted T-cells, there is often a dysregulation of these transcription factors, leading to an impaired ability to regain functional characteristics. Epigenetic changes, including histone modifications and DNA methylation, further solidify the exhausted phenotype.[29-30] The engagement of immune checkpoint pathways contributes to the maintenance of T-cell exhaustion. Chronic stimulation of T-cells can lead to a feedback loop where inhibitory receptor signaling perpetuates the exhausted state. Additionally, the local tumor microenvironment, often characterized by the presence of immunosuppressive factors, can further exacerbate T-cell exhaustion.[31-32]

Exhausted T-cells exhibit reduced functionality, compromising the immune system's ability to control viral replication effectively. This can lead to persistently high viral loads, increasing the risk of disease progression and transmission. T-cell exhaustion can negatively impact the immune response to vaccines, which are crucial for preventing opportunistic infections. Exhausted T-cells are less responsive to vaccination, reducing the effectiveness of immunization efforts in HIV-infected individuals. Chronic HIV infection often leads to immune dysregulation, making individuals more susceptible to co-infections such as tuberculosis and hepatitis. T-cell exhaustion compromises the ability to mount effective immune responses against these pathogens, further complicating the management of HIV. The chronic immune activation and exhaustion associated with HIV can have lasting effects on the immune system, leading to long-term dysregulation and increased risk of chronic diseases. This can impact overall health and quality of life for individuals living with HIV.[33-37] While ART effectively reduces viral loads, its impact on reversing T-cell exhaustion is limited. Early initiation of ART and optimizing treatment regimens are important for preserving T-cell function. Targeting inhibitory receptors such as PD-1 and CTLA-4 with immune checkpoint inhibitors has shown promise in reactivating exhausted T-cells. These therapies aim to block inhibitory signals, enhancing T-cell proliferation and function. Vaccination strategies designed to boost T-cell responses specifically against HIV antigens may provide a means to enhance immune function and overcome exhaustion. Therapeutic vaccines aim to stimulate the immune system and restore T-cell activity. Administering cytokines, such as IL-2, IL-7, and IL-15, can potentially enhance T-cell proliferation and function, counteracting the effects of exhaustion. These cytokines play a role in promoting T-cell survival and activation. Transferring autologous or genetically modified T-cells that are resistant to exhaustion represents a novel approach to restoring immune function in HIV-infected individuals. This strategy aims to enhance the antiviral response by providing functional T-cells that can effectively target HIV.[38-42]

Mechanisms of T-Cell Exhaustion

T-cell exhaustion is a multifaceted process that arises in the context of chronic infections, including HIV. It is characterized by a progressive decline in T-cell effector function, leading to a diminished

ability to control viral replication and respond effectively to pathogens. The mechanisms underlying T-cell exhaustion are complex and involve various cellular and molecular pathways. The primary driver of T-cell exhaustion is prolonged exposure to antigens, such as those presented by persistent HIV infection. In the context of HIV, T-cells are continually stimulated by the presence of viral particles and infected cells, leading to chronic activation. Initially, this activation is essential for mounting an immune response, but over time, the continuous stimulation leads to functional impairment. The persistence of high levels of viral antigens can overwhelm the T-cell response, driving the transition from activation to exhaustion.[43-45] One of the hallmark features of exhausted T-cells is the upregulation of inhibitory receptors on their surface. Key inhibitory receptors include programmed cell death protein 1 (PD-1), cytotoxic T-lymphocyte-associated protein 4 (CTLA-4), and T-cell immunoglobulin and mucin domain-containing protein 3 (TIM-3). The binding of these receptors to their respective ligands transmits negative signals to T-cells, inhibiting their activation and effector functions. For example, PD-1 binding to its ligand (PD-L1) suppresses T-cell receptor (TCR) signaling, leading to reduced cytokine production and impaired proliferation. This upregulation is often a result of sustained antigen exposure and contributes to the overall dysfunction of T-cells. T-cell exhaustion is associated with significant changes in the transcriptional landscape of T-cells. Exhausted T-cells exhibit altered expression of key transcription factors that regulate T-cell function. For instance, T-bet and Eomesodermin (Eomes) are critical for T-cell differentiation and effector functions, while Blimp-1 is associated with terminal differentiation. In exhausted T-cells, the expression of these transcription factors is dysregulated, leading to a shift toward a more quiescent and dysfunctional state. Additionally, transcriptional repression mediated by epigenetic changes, such as histone modifications, reinforces the exhausted phenotype.[46-48]

T-cell exhaustion is also linked to alterations in metabolic pathways. Exhausted T-cells often exhibit a reliance on oxidative phosphorylation rather than glycolysis, which is characteristic of highly activated T-cells. This shift in metabolism can limit the energy supply and substrates necessary for optimal T-cell function, contributing to their impaired ability to proliferate and produce cytokines. Additionally, exhausted T-cells may accumulate toxic metabolites, such as reactive oxygen species (ROS), which can further compromise their function and survival.[49] The immune microenvironment plays a critical role in shaping T-cell responses and can influence the development of exhaustion. In chronic infections like HIV, the presence of immunosuppressive factors, such as regulatory T-cells (Tregs) and myeloid-derived suppressor cells (MDSCs), can contribute to T-cell dysfunction. These cells secrete cytokines and other soluble factors that promote an immunosuppressive environment, further exacerbating T-cell exhaustion. Additionally, chronic inflammation and the presence of viral proteins in the microenvironment can perpetuate T-cell dysfunction.[50] Epigenetic changes, including DNA methylation and histone modifications, are critical for establishing and maintaining T-cell exhaustion. These modifications can lead to stable alterations in gene expression patterns that promote the exhausted phenotype. For example, DNA methylation can silence genes involved in T-cell activation and effector functions, while histone modifications can influence the accessibility of chromatin to transcriptional machinery. Such changes can be long-lasting, making it challenging for exhausted T-cells to recover even after antigen levels decline.[51]

Exhausted T-cells often exhibit dysregulated signaling pathways that are essential for their activation and function. The TCR signaling pathway, which is critical for T-cell activation, can be significantly impaired in exhausted T-cells due to the chronic engagement of inhibitory receptors. Additionally, signaling through co-stimulatory receptors, such as CD28, may be diminished in exhausted T-cells, further compromising their ability to mount an effective immune response. T-cell exhaustion is closely associated with cellular senescence, a state of irreversible cell cycle arrest characterized by altered gene expression and increased pro-inflammatory cytokine production. Exhausted T-cells can acquire a senescent phenotype, contributing to chronic inflammation and immune dysfunction. This senescent state can be associated with telomere shortening, increased expression of senescence-associated β-galactosidase (SA-β-gal), and the secretion of senescence-associated secretory phenotype (SASP) factors, which can negatively impact neighboring cells and further promote immune dysregulation.[49]

Clinical Implications

T-cell exhaustion has significant clinical implications for individuals living with HIV, affecting both disease progression and treatment outcomes. Understanding these implications is essential for developing effective management strategies and improving the quality of life for patients. Below are some key clinical implications associated with T-cell exhaustion in HIV-infected individuals. One of the most critical consequences of T-cell exhaustion is its impact on the ability to control HIV replication. Exhausted T-cells exhibit diminished functionality, including reduced capacity for cytokine production and impaired cytotoxic activity. This dysfunction hinders the immune system's ability to effectively recognize and eliminate HIV-infected cells, leading to persistently high viral loads. As a result, patients with T-cell exhaustion may experience a more rapid progression to AIDS, increased morbidity, and a higher risk of complications associated with chronic HIV infection. Vaccination is a vital strategy for preventing infections and enhancing immune responses in HIV-infected individuals. However, T-cell exhaustion can significantly reduce the efficacy of vaccines. Exhausted T-cells have impaired ability to proliferate and produce protective antibodies in response to vaccination, resulting in suboptimal immune responses. This is particularly concerning in pediatric populations, where effective vaccination is crucial for preventing co-infections. Consequently, HIV-infected individuals may be at increased risk for vaccine-preventable diseases, necessitating alternative approaches to vaccination and immune enhancement.[50]

Chronic HIV infection and the associated T-cell exhaustion can lead to a heightened susceptibility to co-infections, such as tuberculosis (TB), hepatitis, and opportunistic infections. The weakened immune response due to exhausted T-cells limits the body's ability to fight off these pathogens, resulting in a higher incidence of co-infections and related complications. This increased vulnerability can further complicate the management of HIV and lead to higher rates of morbidity and mortality in affected individuals. T-cell exhaustion can have long-lasting effects on the immune system, contributing to chronic immune dysfunction even after viral loads are suppressed by antiretroviral therapy (ART). The persistence of exhausted T-cells can lead to a state of chronic inflammation, which has been associated with various long-term health issues, including

cardiovascular diseases, metabolic disorders, and certain cancers. Understanding the long-term consequences of T-cell exhaustion is essential for developing strategies to monitor and manage the overall health of individuals living with HIV. The presence of T-cell exhaustion can complicate the treatment of HIV infection. While ART is effective in reducing viral loads, its impact on reversing T-cell exhaustion is often limited. Patients with significant T-cell exhaustion may exhibit suboptimal responses to ART, resulting in treatment failure or incomplete viral suppression. This necessitates a more personalized approach to treatment, where clinicians must consider the immune status of the patient in addition to viral load when making management decisions.[51]

Given the clinical challenges posed by T-cell exhaustion, there is an urgent need for therapeutic strategies aimed at reversing this phenomenon. Immune modulation therapies, such as immune checkpoint inhibitors that target PD-1 and CTLA-4, are being investigated for their potential to reinvigorate exhausted T-cells. These therapies could enhance T-cell functionality, improve viral control, and ultimately lead to better health outcomes for individuals living with HIV. Research into combination therapies that integrate ART with immune-modulating agents may provide a comprehensive approach to managing HIV. Early diagnosis and intervention in HIV infection are critical to prevent the establishment of T-cell exhaustion. Initiating ART at the earliest stages of infection can help preserve T-cell function and prevent the progression of immune dysfunction. Screening programs and education initiatives aimed at promoting early testing and treatment for HIV can play a pivotal role in mitigating the impact of T-cell exhaustion on patient health. Given the multifactorial nature of T-cell exhaustion and its clinical implications, a holistic approach to patient management is essential. This includes not only antiviral treatment but also addressing comorbidities, optimizing nutritional status, and providing psychosocial support. Integrating multidisciplinary care teams can enhance overall health and well-being for individuals living with HIV, ultimately improving treatment outcomes and quality of life.[50-52]

Conclusion

T-cell exhaustion represents a significant challenge in the management of HIV infection, profoundly impacting the immune response, disease progression, and overall health of affected individuals. The mechanisms underlying T-cell exhaustion, including chronic antigen exposure, upregulation of inhibitory receptors, transcriptional and metabolic reprogramming, and the influence of the immune microenvironment, contribute to a state of dysfunction that impairs the ability to control viral replication and respond effectively to co-infections. The clinical implications of T-cell exhaustion are far-reaching, as it leads to impaired viral control, reduced vaccine efficacy, increased susceptibility to co-infections, and long-term immune dysfunction. These factors complicate treatment responses and highlight the need for innovative therapeutic strategies that can effectively address T-cell exhaustion. Current antiretroviral therapies, while essential, may not fully restore T-cell function, necessitating the exploration of adjunctive treatments, such as immune checkpoint inhibitors and therapeutic vaccines.

References

1. Obeagu EI, Anyiam AF, Obeagu GU. Managing Anemia in HIV through Blood Transfusions: Clinical Considerations and Innovations. Elite Journal of HIV, 2024; 2(1): 16-30

Citation: Obeagu EI. HIV and T-Cell Exhaustion in Pediatric Populations. Elite Journal of Immunology, 2024; 2(6): 53-62

2. Obeagu EI, Obeagu, GU. Counting Cells, Shaping Fates: CD4/CD8 Ratios in HIV. EliteJournal of Scientific Research and Review, 2024; 2(1): 37-50
3. Obeagu EI, Obeagu GU. Hematological Changes Following Blood Transfusion in Young Children with Severe Malaria and HIV: A Critical Review. Elite Journal of Laboratory Medicine, 2024; 2(1): 33-45
4. Obeagu EI, Obeagu GU. The Role of Blood Transfusion Strategies in HIV Management: Current Insights and Future Directions. Elite Journal of Medicine, 2024; 2(1):10-22
5. Lewis DB, Weitkamp JH, Levy O. Developmental immunology and role of host defenses in fetal and neonatal susceptibility to infection. In Remington and Klein's Infectious Diseases of the Fetus and Newborn Infant 2025: 73-159. Elsevier.
6. Netea MG. Training innate immunity: the changing concept of immunological memory in innate host defence. European journal of clinical investigation. 2013;43(8):881-884.
7. Obeagu EI, Obeagu GU. Eosinophil Dynamics in Pregnancy among Women Living with HIV: A Comprehensive Review. Int. J. Curr. Res. Med. Sci. 2024;10(1):11-24.
8. Viola N, Kimono E, Nuruh N, Obeagu EI. Factors Hindering Elimination of Mother to Child Transmission of HIV Service Uptake among HIV Positive Women at Comboni Hospital Kyamuhunga Bushenyi District. Asian Journal of Dental and Health Sciences. 2023;3(2):7-14.
9. Obeagu EI, Obeagu GU. Transfusion-Related Complications in Children Under 5 with Coexisting HIV and Severe Malaria: A Review. Int. J. Curr. Res. Chem. Pharm. Sci. 2024;11(2):9-19.
10. Obeagu EI, Obeagu GU, Hauwa BA, Umar AI. Neutrophil Dynamics: Unveiling Their Role in HIV Progression within Malaria Patients. Journal home page: http://www. journalijiar. com.;12(01).
11. Obeagu EI, Obeagu, GU. P-Selectin and Platelet Activation in HIV: Implications for Antiviral Therapy. Elite Journal of Scientific Research and Review, 2024; 2(1): 17-41
12. Obeagu EI, Obeagu GU. The Intricate Relationship Between Erythropoietin and HIV-Induced Anemia: Unraveling Pathways for Therapeutic Insights. Int. J. Curr. Res. Chem. Pharm. Sci. 2024;11(2):30-40.
13. Arikawa S, Rollins N, Newell ML, Becquet R. Mortality risk and associated factors in HIV-exposed, uninfected children. Tropical Medicine & International Health. 2016;21(6):720-734.
14. Brennan AT, Bonawitz R, Gill CJ, Thea DM, Kleinman M, Useem J, Garrison L, Ceccarelli R, Udokwu C, Long L, Fox MP. A meta-analysis assessing all-cause mortality in HIV-exposed uninfected compared with HIV-unexposed uninfected infants and children. Aids. 2016;30(15):2351-2360.
15. Obeagu EI, Anyiam AF, Obeagu GU. Erythropoietin Therapy in HIV-Infected Individuals: A Critical Review. Elite Journal of HIV, 2024; 2(1): 51-64
16. Obeagu EI, Obeagu GU. Strength in Unity: Building Support Networks for HIV Patients in Uganda . Elite Journal of Medicine, 2024; 2(1): 1-16
17. Obeagu EI, Obeagu GU. Eosinophilic Changes in Placental Tissues of HIV-Positive Pregnant Women: A Review. Elite Journal of Laboratory Medicine, 2024; 2(1): 14-32

Citation: Obeagu EI. HIV and T-Cell Exhaustion in Pediatric Populations. Elite Journal of Immunology, 2024; 2(6): 53-62

18. Obeagu EI, Obeagu, GU. The Crucial Role of Erythropoietin in Managing Anemia in HIV: A Review. Elite Journal of Scientific Research and Review, 2024; 2(1): 24-36
19. Obeagu EI, Ubosi NI, Obeagu GU, Obeagu AA. Nutritional Strategies for Enhancing Immune Resilience in HIV: A Review. Int. J. Curr. Res. Chem. Pharm. Sci. 2024;11(2):41-51.
20. Obeagu EI, Nweke JO. Neonatal Immune Development in the Context of HIV Infection: A Review. Elite Journal of Immunology. 2024;2(5):29-38.
21. Obeagu EI. Immune Dysregulation in HIV-Positive Neonates: A Review. Elite Journal of Laboratory Medicine. 2024;2(6):49-66.
22. Obeagu EI, Obeagu GU. Maternal Influence on Infant Immunological Responses to HIV: A Review. Elite Journal of Laboratory Medicine. 2024;2(1):46-58.
23. Obeagu EI, Obeagu GU. An update on Early Immunological Markers in HIV-Exposed Infants. Elite Journal of Immunology. 2024;2(6):15-25.
24. Kampmann B, Jones CE. Factors influencing innate immunity and vaccine responses in infancy. Philosophical Transactions of the Royal Society B: Biological Sciences. 2015 Jun 19;370(1671):20140148.
25. Obeagu EI. HIV-Specific T-Cell Responses in Infants: A Review. Elite Journal of Medical Sciences. 2024;2(6):10-23.
26. Diamond MS, Kanneganti TD. Innate immunity: the first line of defense against SARS-CoV-2. Nature immunology. 2022;23(2):165-176.
27. Amarante-Mendes GP, Adjemian S, Branco LM, Zanetti LC, Weinlich R, Bortoluci KR. Pattern recognition receptors and the host cell death molecular machinery. Frontiers in immunology. 2018; 9:2379.
28. Andoniou CE, Andrews DM, Degli-Esposti MA. Natural killer cells in viral infection: more than just killers. Immunological reviews. 2006;214(1):239-250.
29. Mayer LS, Uciechowski P, Meyer S, Schwerdtle T, Rink L, Haase H. Differential impact of zinc deficiency on phagocytosis, oxidative burst, and production of pro-inflammatory cytokines by human monocytes. Metallomics. 2014;6(7):1288-1295.
30. Basha S, Surendran N, Pichichero M. Immune responses in neonates. Expert review of clinical immunology. 2014;10(9):1171-1184.
31. Maródi L. Neonatal innate immunity to infectious agents. Infection and immunity. 2006;74(4):1999-2006.
32. Obeagu EI, Elamin EAI Obeagu GU. Understanding the Intersection of Highly Active Antiretroviral Therapy and Platelets in HIV Patients: A Review. Elite Journal of Haematology, 2024; 2(3): 111-117
33. Obeagu EI, Obeagu GU. Neonatal Outcomes in Children Born to Mothers with Severe Malaria, HIV, and Transfusion History: A Review. Elite Journal of Nursing and Health Science, 2024; 2(3): 38-58
34. Obeagu EI. Erythropoietin and the Immune System: Relevance in HIV Management. Elite Journal of Health Science, 2024; 2(3): 23-35
35. Obeagu EI, Obeagu GU. Understanding Immune Cell Trafficking in Tuberculosis-HIV Coinfection: The Role of L-selectin Pathways. Elite Journal of Immunology, 2024; 2(2): 43-59

Citation: Obeagu EI. HIV and T-Cell Exhaustion in Pediatric Populations. Elite Journal of Immunology, 2024; 2(6): 53-62

36. Obeagu EI, Obeagu GU. Anemia and Erythropoietin: Key Players in HIV Disease Progression. Elite Journal of Haematology, 2024; 2(3): 42-57
37. Obeagu EI, Ayogu EE, Obeagu GU. Impact on Viral Load Dynamics: Understanding the Interplay between Blood Transfusion and Antiretroviral Therapy in HIV Management. Elite Journal of Nursing and Health Science, 2024; 2(2): 5-15
38. Obeagu EI, Obeagu GU. Immune Modulation in HIV-Positive Neonates: Insights and Implications for Clinical Management. Elite Journal of Nursing and Health Science, 2024; 2(3): 59-72
39. Blanco JR, Negredo E, Bernal E, Blanco J. Impact of HIV infection on aging and immune status. Expert Review of Anti-infective Therapy. 2021;19(6):719-731.
40. Olbrich L, Stockdale L, Basu Roy R, Song R, Cicin-Sain L, Whittaker E, Prendergast AJ, Fletcher H, Seddon JA. Understanding the interaction between cytomegalovirus and tuberculosis in children: the way forward. PLoS Pathogens. 2021;17(12): e1010061.
41. Fok ET, Davignon L, Fanucchi S, Mhlanga MM. The lncRNA connection between cellular metabolism and epigenetics in trained immunity. Frontiers in Immunology. 2019; 9:3184.
42. Cuenca AG, Wynn JL, Moldawer LL, Levy O. Role of innate immunity in neonatal infection. American journal of perinatology. 2013;30(02):105-112.
43. Obeagu EI, Obeagu GU. Maternal Influence on Infant Immunological Responses to HIV: A Review. Elite Journal of Laboratory Medicine. 2024;2(1):46-58.
44. Obeagu EI, Obeagu GU. Impact of Maternal Eosinophils on Neonatal Immunity in HIV-Exposed Infants: A Review. Elite Journal of Immunology. 2024;2(3):1-8.
45. Lowenthal ED, Bakeera-Kitaka S, Marukutira T, Chapman J, Goldrath K, Ferrand RA. Perinatally acquired HIV infection in adolescents from sub-Saharan Africa: a review of emerging challenges. The Lancet infectious diseases. 2014;14(7):627-639.
46. Obeagu EI, Chukwu PH. HIV and Natural Killer (NK) Cell Responses in Neonates: A Review. Elite Journal of Immunology. 2024;2(5):39-49.
47. Ruck C, Reikie BA, Marchant A, Kollmann TR, Kakkar F. Linking susceptibility to infectious diseases to immune system abnormalities among HIV-exposed uninfected infants. Frontiers in immunology. 2016; 7:310.
48. Langel SN, Blasi M, Permar SR. Maternal immune protection against infectious diseases. Cell Host & Microbe. 2022 May 11;30(5):660-674.
49. Obeagu EI. Markers of Immune Activation in HIV-Exposed Infants. Elite Journal of Health Science. 2024;2(6):1-4.
50. Obeagu EI, Obeagu GU. Maternal Eosinophilic Responses in HIV-Positive Pregnant Women: Unraveling Immunological Dynamics for Improved Maternal-Fetal Health. Elite Journal of Immunology. 2024;2(1):47-64.
51. Obeagu EI, Obeagu GU. Impact of Breastfeeding on Infant Immune Responses in the Context of HIV. Elite Journal of Nursing and Health Science. 2024;2(4):23-39.
52. Obeagu EI. HIV and Innate Immune Memory in Neonates. Elite Journal of Immunology, 2024; 2(6): 44-52

Citation: Obeagu EI. HIV and T-Cell Exhaustion in Pediatric Populations. Elite Journal of Immunology, 2024; 2(6): 53-62

Citation: Obeagu EI. HIV and T-Cell Exhaustion in Pediatric Populations. Elite Journal of Immunology, 2024; 2(6): 53-62